

## REMARKS

The Office Action mailed June 14, 2006, has been carefully reviewed and the following remarks have been made in consequence thereof.

Claims 1-45 are pending in this application. Claims 1-45 are subject to a Restriction Requirement.

The Office has asserted that there are thirteen groups of claims in this application. The first Group, Group I, contains Claims 1-6, 35-36 and 38, drawn to a biosensor. The second Group, Group II, contains Claims 7-8, drawn to a method of screening for a modulator utilizing biosensor. The third Group, Group III, contains Claims 9-10, drawn to a method of determining signal transduction utilizing biosensor. The fourth Group, Group IV, contains Claims 11-16, drawn to a method for identifying drugs utilizing mammalian alpha subunit. The fifth Group, Group V, contains Claims 17, 18, 39 and 40, drawn to a non-invasive method for screening for antagonist utilizing agonist and candidate drug. The sixth Group, Group VI, contains Claims 19-24, drawn to a non-invasive method of screening for natural and synthetic drugs that bind to orphan receptors. The seventh Group, Group VII, contains Claims 25-30, drawn to a method of identifying candidate inverse agonists utilizing biosensors. The eighth group, Group VIII, contains Claims 31, 37, and 39, drawn to a classification method for natural and synthetic modulators. The ninth group, Group IX, contains Claim 32, drawn to a method of increasing the number of receptor types utilizing mutant biosensor. The tenth group, Group X, contains Claims 33 and 34, drawn to a method of altering intensity of FRET. The eleventh group, Group XI, contains Claims 41 and 42, drawn to a live functional biosensor comprising alpha subunit substitute of various receptors. The twelfth group, Group XII, drawn to a method of identifying and classifying modulators


of various receptor types. The thirteenth group, Group XIII, contains Claim 45, drawn to a method of classifying candidate therapeutic compounds utilizing biosensor cells comprising alpha subunit, beta subunit and gamma subunit.

In response to the Restriction Requirement set forth in the Office Action, Applicants, with traverse, elect for prosecution in this application all claims belonging to Group I, i.e., Claims 1-6, 35-36 and 38.

Reconsideration of the Restriction Requirement imposed under 35 U.S.C. § 121 is respectfully requested. Additionally, requirements for election are not mandatory under 35 U.S.C. 121. The requirement for election is traversed because the inventions set out by the claims in Groups I, II, III, IV, V, VI, VII, VIII, IX, X IX, XII, and XIII are clearly related. Applicants submit that a thorough search and examination of any claim group would be relevant to the examination of the other group and would not be a serious burden on the Examiner. For at least the reasons set forth above, Applicant respectfully requests that the Restriction Requirement be withdrawn.

In view of the foregoing remarks, all the claims now active in this application are believed to be in condition for allowance. Reconsideration and favorable action with respect to all the pending claims is respectfully solicited.

Respectfully submitted,



---

Jason P. Gross  
Reg. No.: 58,098  
ARMSTRONG TEASDALE LLP  
One Metropolitan Square, Suite 2600  
St. Louis, Missouri 63102-2740  
(314) 621-5070